Company Overview and News

Your Daily Pharma Scoop: Conatus Data, Solid Biosciences' SGT-001, Ultragenyx's Crysvita Approved

2018-04-19 seekingalpha
Today we will discuss Conatus (NASDAQ:CNAT), which fell more than 4% in regular trading even as the company reported promising data with IDN-7314.
Upvote Downvote

Sohn Conference

2018-04-19 cnbc
CNBC's Leslie Picker reports on a new study that digs deeper into the connection between testosterone and performance on Wall Street.
Upvote Downvote

INSYS Therapeutics to Advance Clinical Research of Dronabinol Inhalation Using Novel Breath-Actuated Device

2018-04-18 globenewswire
PHOENIX, April 18, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced plans to advance clinical research of dronabinol inhalation using a novel and patented breath-actuated device—licensed from U.K.-based Senzer Ltd. and accepted by the U.S. Food and Drug Administration (FDA) under an investigational new drug (IND) filing—in the second half of 2018.
Upvote Downvote

Drug Made From Cannabis Plant Gets Backing From FDA Staff - Bloomberg

2018-04-17 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
Upvote Downvote

INSY / Insys Therapeutics Inc. DEF 14A

Upvote Downvote

Will Opiant Pharma Solve The Biggest Crisis That The FDA Is Currently Facing?

2018-04-11 seekingalpha
Opioid epidemic continues to be one of the biggest challenges that the FDA is currently facing.
Upvote Downvote

GW Pharma's Cannabinoid-Based Epilepsy Position Continues To Strengthen

2018-04-02 seekingalpha
Childhood Epilepsy solutions are just the first phase in a range of treatments for GW Pharma.
Upvote Downvote

INSYS Therapeutics Appoints Trudy Vanhove to Board of Directors

2018-04-02 globenewswire
PHOENIX, April 02, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced the appointment of Trudy Vanhove as a new independent member of its Board of Directors. Given her extensive experience in clinical development and medical affairs, Dr. Vanhove will also serve on the Board’s R&D committee.
Upvote Downvote

Insys Recommits to "High Ethical Standards" After Five Doctors Indicted on Federal Bribery, Kickback Charges

2018-03-24 genengnews
Insys Therapeutics today responded to the federal indictment Friday of five doctors on charges of conspiring to receive bribes and kickbacks from the company by expressing a commitment to “high ethical standards” and cooperation with authorities.
Upvote Downvote

Is Insys At Risk?

2018-03-20 seekingalpha
Last week five doctors were charged with writing fentanyl prescriptions in exchange for kickbacks from INSY.
Upvote Downvote

5 doctors charged with taking kickbacks to tout painkiller

NEW YORK (AP) — Five New York City doctors were arrested Friday on charges that they accepted bribes and kickbacks from an Arizona-based pharmaceutical company to prescribe large volumes of a highly addictive painkiller.
Upvote Downvote

UPDATE 1-Five New York doctors charged with taking kickbacks from Insys

2018-03-16 reuters
NEW YORK (Reuters) - Federal prosecutors charged five New York doctors on Friday with taking kickbacks from Insys Therapeutics Inc in exchange for prescribing the company’s potent spray version of the opioid drug fentanyl.
Upvote Downvote

Five New York doctors charged with taking kickbacks from Insys

2018-03-16 reuters
March 16 (Reuters) - Federal prosecutors have charged five New York doctors with taking kickbacks from Insys Therapeutics Inc in exchange for prescribing the company’s potent spray version of the opioid drug fentanyl.
Upvote Downvote

INSY / Insys Therapeutics Inc. 10-K (Annual Report)

insy-10k_20171231.htm Table of Contents
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 45824V209